MicroRNAs and chromosomal abnormalities in cancer cells - PubMed (original) (raw)
Review
. 2006 Oct 9;25(46):6202-10.
doi: 10.1038/sj.onc.1209910.
Affiliations
- PMID: 17028600
- DOI: 10.1038/sj.onc.1209910
Review
MicroRNAs and chromosomal abnormalities in cancer cells
G A Calin et al. Oncogene. 2006.
Abstract
Over the past five decades, a plethora of nonrandom chromosomal abnormalities have been consistently reported in malignant cells facilitating the identification of cancer-associated protein coding oncogenes and tumor suppressors. The genetic dissection of hot spots for chromosomal abnormalities in the age of the sequenced human genome resulted in the discovery that microRNA (miRNA) genes, encoding for a class of small noncoding RNAs, frequently resides in such genomic regions. The combination of nonrandom chromosomal abnormalities and other types of genetic alterations or epigenetic events contribute to downregulation or overexpression of miRNAs. The consequent abnormal expression of miRNAs affect cell cycle, survival and differentiation programs and selective targeting of these noncoding genes could provide novel therapeutic options for killing the malignant cells.
Similar articles
- Investigation of microRNA alterations in leukemias and lymphomas.
Calin GA, Croce CM. Calin GA, et al. Methods Enzymol. 2007;427:193-213. doi: 10.1016/S0076-6879(07)27011-9. Methods Enzymol. 2007. PMID: 17720486 - MicroRNAs as oncogenes.
Hammond SM. Hammond SM. Curr Opin Genet Dev. 2006 Feb;16(1):4-9. doi: 10.1016/j.gde.2005.12.005. Epub 2005 Dec 19. Curr Opin Genet Dev. 2006. PMID: 16361094 Review. - MicroRNAs in human cancer: from research to therapy.
Negrini M, Ferracin M, Sabbioni S, Croce CM. Negrini M, et al. J Cell Sci. 2007 Jun 1;120(Pt 11):1833-40. doi: 10.1242/jcs.03450. J Cell Sci. 2007. PMID: 17515481 - MicroRNAs: novel regulators in the hallmarks of human cancer.
Ruan K, Fang X, Ouyang G. Ruan K, et al. Cancer Lett. 2009 Nov 28;285(2):116-26. doi: 10.1016/j.canlet.2009.04.031. Epub 2009 May 22. Cancer Lett. 2009. PMID: 19464788 Review. - Expression profiling of microRNAs in cancer cells: technical considerations.
Sioud M, Cekaite L. Sioud M, et al. Methods Mol Biol. 2008;439:179-90. doi: 10.1007/978-1-59745-188-8_12. Methods Mol Biol. 2008. PMID: 18370103
Cited by
- MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.
Zhang Y, Geng L, Talmon G, Wang J. Zhang Y, et al. J Biol Chem. 2015 Mar 6;290(10):6215-25. doi: 10.1074/jbc.M114.620252. Epub 2015 Jan 23. J Biol Chem. 2015. PMID: 25616665 Free PMC article. - miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth.
Prashad N. Prashad N. Oncotarget. 2018 Sep 4;9(69):33186-33201. doi: 10.18632/oncotarget.26046. eCollection 2018 Sep 4. Oncotarget. 2018. PMID: 30237861 Free PMC article. - The cytotoxic ribonuclease onconase targets RNA interference (siRNA).
Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z. Zhao H, et al. Cell Cycle. 2008 Oct;7(20):3258-61. doi: 10.4161/cc.7.20.6855. Epub 2008 Oct 25. Cell Cycle. 2008. PMID: 18927512 Free PMC article. - Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement.
Kim S, Kim H, Kang H, Kim J, Eom H, Kim T, Yoon SS, Suh C, Lee D; Korean Society of Hematology Lymphoma Working Party. Kim S, et al. J Hematol Oncol. 2013 Oct 3;6:76. doi: 10.1186/1756-8722-6-76. J Hematol Oncol. 2013. PMID: 24220305 Free PMC article. - Identification of circulating microRNAs in HNF1A-MODY carriers.
Bonner C, Nyhan KC, Bacon S, Kyithar MP, Schmid J, Concannon CG, Bray IM, Stallings RL, Prehn JH, Byrne MM. Bonner C, et al. Diabetologia. 2013 Aug;56(8):1743-51. doi: 10.1007/s00125-013-2939-4. Epub 2013 May 15. Diabetologia. 2013. PMID: 23674172
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous